Project Grant R01CA311995
Award Date 5/11/26
Completion Date 4/30/31
Dollars Obligated $700K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $675,009 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2026, with a completion date of July 31, 2031. This research initiative, led by a cross-disciplinary collaboration between experts in RAS (Rat sarcoma) protein drugging and cancer signaling, focuses on developing novel covalent inhibitors targeting RAS Q61 mutations...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $640,466 Project Grant to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) effective June 1, 2026 through May 31, 2031. This five-year initiative focuses on developing a novel class of covalent protein radiopharmaceuticals for targeted radionuclide therapy in cancer treatment. The project involves designing and genetically incorporating latent...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $658,722 to The Regents of the University of California, San Francisco (UCSF) under the Cancer Treatment Research program (CFDA 93.395) on March 12, 2026, with completion targeted for February 28, 2031. The award supports fundamental cancer research investigating the mechanisms by which telomerase reverse transcriptase (TERT) promoter mutations enable tumor cell immortality—a central hallmark of cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of California, San Francisco a $680,597 Project Grant under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, with an anticipated completion date of March 31, 2031. This five-year award funds genome-wide in vivo CRISPR screening research designed to identify G-protein-coupled receptor (GPCR) pathway targets that enhance chimeric antigen receptor T (CAR-T) cell therapies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $677,787 to The Regents of the University of California, San Francisco on August 26, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports a five-year research initiative (through July 31, 2030) investigating AIRE-expressing tumor-associated macrophages (AIRE+ TAMs) as novel mediators of tumor immune evasion. The research aims to characterize the molecular and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Regents of the University of California, San Francisco a $680,598 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, with a completion date of August 31, 2030. The award supports fundamental research focused on decoding the Cullin-5 (CUL5) E3 ubiquitin ligase complex to engineer therapeutic T cells with enhanced durability and sustained effector function. The project...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $185,760.00 to The Regents of the University of California, San Francisco under the Cancer Research Manpower program (CFDA 93.398) on July 7, 2025. This Project Grant funds research aimed at enhancing treatment outcomes for metastatic castration-resistant prostate cancer (MCRPC) through the development of novel tumor-targeted combination therapy. The primary research deliverable involves creating a single...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $399,829 to the University of Maryland, Baltimore on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) for research addressing drug resistance in acute leukemias. The project, titled "Protein Degradation Strategies to Overcome Menin Drug Resistance in Acute Leukemias," will be completed by April 30, 2028. The research focuses on developing proteolysis-targeting chimera...